$BMSN Promo In Play:
Received email 10 Jan 2013 @ 10:46pm CST
from Exclusivestocks and Awesome Penny Picks:
BMSN ~ Our New Vip Pick and the Top Stem Cell Biotech Stock trading at only .0013 cents with huge upside.. BMSN is our next AMBS type play.. Members if you recall AMBS was our last Biotech Vip Pick at .005 cents and it ran to a high of .19 cents recently.. BMSN is our New Biotech Vip Pick and its chart is screaming breakout right now.. BMSN is Pending to Announce FDA IND Application News for its Drug, Safety & Research News on its Drug and Merger News so act fast on this one Members..
BMSN is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications. Regen BioPharma, Inc., a subsidiary of BMSN, is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
BMSN has Assessed over 20,000 Stem Cell related issued Patents, narrowed down to 2000 Patents with commercial applicability, and further identified 30 Patents available for Licensing.
BMSN seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies. HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally." Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
BMSN recently announced Thomas E. Ichim, PhD (view here) has joined the management team of its Regen BioPharma, Inc. subsidiary as Chief Scientific Officer and Director of Research.
Regen BioPharma is the company's translational medicine platform for the rapid commercialization of stem cell therapies. Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune. David Koos, Chief Executive Officer of BMSN, stated: "Dr. Ichim is a seasoned biotechnology executive with a track record of scientific excellence. We now have a world-class team to lead our efforts to commercialize stem cell therapies."
BMSN ~ Is Pending to Announce FDA IND Application Breaking News, Safety News and Research News any day now so act fast Members.. BMSN Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy
BMSN Also Developing Two Solutions for Restoring Blood Production That Lack the Adverse Effects of Current Bone Marrow Stimulating Growth Factors
SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing. Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.
The results of Regen's study will provide the safety profile data required for filing of an Investigational New Drug (IND) application for the product with the US Food and Drug Administration . Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.
HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."
Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
BMSN ~ Announced that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing.
Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study."
BMSN ~ Breaking Merger News is Pending.. The CEO of BMSN has mentioned its Pending to Announce Merger News with its Majority Owned Subsidiary Entest BioMedical, Inc (OTCBB: ENTB)..
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of BMSN. The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues. Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer.
The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment. Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 BB will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.
BMSN Shows a Monster Breakout coming now as well as the Company's 10K due out on January 15th so act fast on this one Members..
Make sure to Get ready tomorrow morning and pull up BMSN on your quotes and charts cause this one looks to run high short term..
AI
